José Ponce

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology · 2018 · 744 citations

Breast Oncology, Parp Inhibitor Veliparib, Medicine +7

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Charles E. Geyer, William M. Sikov, Jens Huober et al. · Annals of Oncology · 2022 · 199 citations · Full text

Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging–Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study

Miguel Nogué, Antonieta Salud, Pilar Vicente et al. · The Oncologist · 2011 · 154 citations · Full text

Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.

Ingela Wiklund, Bardhan Kd, S. Müller‐Lissner et al. · PubMed · 1998 · 116 citations

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

Gloria Peiró, Fernando Ortiz-Martínez, Alberto Gallardo et al. · British Journal of Cancer · 2014 · 90 citations · Full text